Meeder Asset Management’s Momenta Pharmaceuticals, Inc. MNTA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q4 | – | Sell |
-36
| Closed | -$2K | – | 2428 |
|
|
2020
Q3 | $2K | Sell |
36
-6,489
| -99% | -$269K | ﹤0.01% | 1901 |
|
|
2020
Q2 | $215K | Sell |
6,525
-934
| -13% | -$29.7K | 0.01% | 584 |
|
|
2020
Q1 | $202K | Buy |
7,459
+5,038
| +208% | +$140K | 0.02% | 562 |
|
|
2019
Q4 | $48K | Buy |
2,421
+1,897
| +362% | +$30.3K | ﹤0.01% | 1033 |
|
|
2019
Q3 | $7K | Buy |
+524
| New | +$6.33K | ﹤0.01% | 1677 |
|
|
2019
Q1 | – | Sell |
-3,974
| Closed | -$44K | – | 1947 |
|
|
2018
Q4 | $44K | Sell |
3,974
-535
| -12% | -$7.45K | ﹤0.01% | 847 |
|
|
2018
Q3 | $119K | Sell |
4,509
-3,096
| -41% | -$83.7K | 0.01% | 608 |
|
|
2018
Q2 | $156K | Buy |
7,605
+6,947
| +1,056% | +$149K | 0.01% | 545 |
|
|
2018
Q1 | $12K | Sell |
658
-39
| -6% | -$650 | ﹤0.01% | 1025 |
|
|
2017
Q4 | $10K | Buy |
697
+123
| +21% | +$1.66K | ﹤0.01% | 1134 |
|
|
2017
Q3 | $10K | Hold |
574
| – | – | ﹤0.01% | 1088 |
|
|
2017
Q2 | $10K | Buy |
574
+351
| +157% | +$5.34K | ﹤0.01% | 1005 |
|
|
2017
Q1 | $3K | Hold |
223
| – | – | ﹤0.01% | 1309 |
|
|
2016
Q4 | $3K | Buy |
+223
| New | +$2.94K | ﹤0.01% | 919 |
|
Meeder Asset Management's MNTA Position: Q4 2020 in Review
Meeder Asset Management sold out of Momenta Pharmaceuticals, Inc. (MNTA) in Q4 2020, closing a stake of 36 shares — an estimated $2K sold.
Meeder Asset Management first reported a position in MNTA in Q4 2016 and held it in 14 quarters. The position peaked at $215K in Q2 2020. 0 funds tracked by Wall St. Rank hold MNTA as of Q4 2020.
- Meeder Asset Management reported no remaining Momenta Pharmaceuticals, Inc. position as of Q4 2020 after selling out during the quarter.
- Meeder Asset Management sold 36 Momenta Pharmaceuticals, Inc. shares in Q4 2020, an estimated $2K.
- Meeder Asset Management first reported a position in Momenta Pharmaceuticals, Inc. in Q4 2016 and held it in 14 quarters.
- Meeder Asset Management's Momenta Pharmaceuticals, Inc. position peaked at $215K in Q2 2020.
- 0 funds tracked by Wall St. Rank held Momenta Pharmaceuticals, Inc. as of Q4 2020.
Based on Meeder Asset Management's 13F filing for Q4 2020, filed 9 Feb 2021.